Welcome to our dedicated page for Medtronic plc SEC filings (Ticker: MDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Medtronic plc reported insider equity activity for EVP Michael Marinaro. On July 31, 2026, 3,356 ordinary shares were withheld at $85.39 per share to satisfy tax liabilities on previously vested restricted stock units. On August 3, 2026, he received grants of 10,960 and 46,147 restricted stock units with multi‑year vesting, 27,400 performance share units that can yield up to 65,760 shares based on performance, and 77,848 stock options exercisable at $86.68 per share expiring in 2036.
Medtronic plc EVP & President Cardiovascular Harry Skip Kiil received several equity awards. On August 3, 2026 he was granted 23,074 performance share units that may result in between 0 and 55,378 shares depending on three-year performance measured through April 27, 2029, 65,556 stock options with an $86.68 exercise price expiring in 2036, and 9,230 restricted stock units that vest fully on the third anniversary of grant.
On July 31, 2026, 3,074 ordinary shares were withheld at $85.39 per share to satisfy tax obligations upon the vesting of previously granted restricted stock units.
Medtronic Chairman and CEO Geoffrey Martha reported multiple equity awards. On August 3, 2026 he received 103,831 Performance Share Units, 41,533 restricted stock units, and two stock option grants for 295,002 and 273,150 shares at $86.6800 per share, with options vesting 25% annually and expiring August 3, 2036. PSU payouts can range from 0 to 249,194 shares based on performance through April 27, 2029. On July 31, 2026, 15,810 shares were withheld to cover taxes on previously vested restricted stock units.
Michelle Quinn, EVP, GC and Secretary of Medtronic plc, reported a Form 4 transaction where 2,069 Ordinary Shares were withheld to pay taxes upon the vesting of previously granted restricted stock units. After this tax-withholding disposition, she directly holds 20,375 Ordinary Shares, including 697 acquired through dividend reinvestment.
Medtronic plc senior vice president and chief HR officer Walter Matthew R. completed an open-market sale of 3,102 Ordinary Shares of Medtronic on July 8, 2026 at a price of $83.15 per share.
After this transaction, he directly owns 35,694 Ordinary Shares, so the sale represents a relatively small portion of his overall holdings. His reported holdings also include 107 shares acquired through Medtronic’s Employee Stock Ownership Plan since his prior report.
MDT submitted a Form 144 notice related to the proposed sale of Common stock. The filing lists multiple prior issuances and acquisition events (ESPP purchases, restricted stock vesting, dividend reinvestment) with dates and per-event share counts included in the schedule.
Medtronic plc EVP & President, Neuroscience Thompson Kweli filed an initial Form 3 showing his current equity holdings in the company. He directly owns 30,017.737 ordinary shares and holds multiple stock option grants with varying exercise prices and expirations, plus performance share units that may convert into additional shares based on future vesting and performance conditions.
Medtronic plc provides a detailed overview of its global medical technology business, risks, and strategic priorities. The company operates across three main portfolios — Cardiovascular, Neuroscience, and Medical Surgical — offering devices from cardiac rhythm management and transcatheter valves to neuromodulation, surgical robotics, and acute care monitoring.
Medtronic highlights a major portfolio shift: its Diabetes Business is being separated into MiniMed Group, Inc., which completed an initial public offering in March 2026. The report also emphasizes heavy investment in R&D, expanded use of data, AI and automation, and a broad intellectual property base in an industry with intense competition and frequent litigation.
The company underscores human capital as a key asset, with over 95,000 employees, strong pay-equity metrics, and extensive learning programs. It also devotes substantial discussion to regulatory, reimbursement, data-privacy, trade, and environmental frameworks that shape how its products are developed, approved, manufactured, and paid for worldwide, including EU MDR, GDPR, and evolving AI regulation.
Medtronic plc executive Harry Skip Kiil reported selling Ordinary Shares in two open-market transactions. On June 8, 2026, he sold a total of 4,189 Medtronic Ordinary Shares in the open market at prices around $80.44–$80.45 per share. These are non-derivative transactions reported as direct ownership and represent routine insider sales rather than option exercises or gifts.